Autologous T-Cell Transplant with Vaccine and Indinavir in Pediatric Sarcomas

Phase 2, open-label, single-arm trial of indinavir in Ewing sarcoma and alveolar rhabdomyosarcoma (ARMS), sponsored by National Cancer Institute. Primary endpoints: Number of Participants With an Immune Response to Tumor-specific and Non-tumor Specific Peptides, The Percent of Patients Who Recover CD4 Counts Within 6 Months of Completion of Chemotherapy and 3 more. Started Dec 1996; status: completed.